60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Saturday,Weiss Ratings reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, January 10th.

60 Degrees Pharmaceuticals Stock Up 0.3 %

SXTP opened at $0.83 on Friday. 60 Degrees Pharmaceuticals has a twelve month low of $0.70 and a twelve month high of $11.01. The company’s 50-day moving average price is $1.18 and its two-hundred day moving average price is $1.02. The stock has a market cap of $1.90 million, a price-to-earnings ratio of -0.08 and a beta of 4.40.

Insider Activity at 60 Degrees Pharmaceuticals

In related news, CEO Geoffrey S. Dow bought 35,823 shares of the company’s stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the completion of the transaction, the chief executive officer now directly owns 94,580 shares in the company, valued at approximately $120,116.60. The trade was a 60.97 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have bought 66,372 shares of company stock worth $82,410. Company insiders own 10.27% of the company’s stock.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.